Egle Tx
Founded 2020 · 52 employees on LinkedIn · 3 known investors
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
Founders & leadership
Board
MD
Michel DetheuxinChairman
Investors · 3
Frequently asked questions
- What does Egle Tx do?
- Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
- Who are Egle Tx's investors?
- Egle Tx's investors include EQT Life Sciences, Fund+, JDRF T1D Fund.